+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetes Care Drugs Market 2020-2026

  • PDF Icon


  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129672
Global Diabetes Care Drugs Market Size, Share & Trends Analysis Report by Drug Class (Insulins, Non-Insulin Injectable Drugs, Oral Anti-Diabetic Drugs, and Combination Drugs), and Forecast, 2020-2026
The global diabetes care drug market is projected to grow at a steady CAGR during the forecast period. The primary factors that are driving the growth of the global diabetes care drugs industry include the rising prevalence of diabetes amongst the peoples across the globe. Further, the rising level of stress, changing lifestyles, excessive consumption of alcohol, smoking, and other junk food consumption that elevated the body’s sugar levels further leads to the development of diabetes among people and hence create demand for drugs to treat the disease. In addition, advancements in drug manufacturing along with the availability of fast-acting drugs also fuel the market growth during the forecast period. However, the availability of alternative products such as diabetes care devices serves as a restricting factor for the growth of the market.

The global diabetes care drugs market is segmented on the basis of drug class as insulins, non-insulin injectable drugs, oral anti-diabetic drugs, and combination drugs. Insulins are amongst the most consumed and favored drug, owing to its fast- and long-action properties. Based on the geographic viewpoint, the global diabetes care drugs market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to hold a considerable share in the market. Asia-Pacific is estimated to exhibit a significant growth rate in the market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Boehringer Ingelheim International GmbH, Sanofi SA, Novo Nordisk A/S, Eli Lilly and Co., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Co., Johnson & Johnson Services Inc., Novartis International AG, Pfizer Inc., and Takeda Pharmaceuticals Co.Ltd., are some of the prominent players operating in the global diabetes care drugs market. In March 2019, Novo Nordisk announced its plan to invest around $98 million in upgrading and expanding the insulin drug manufacturing facility in Kalundborg, Denmark. Such efforts by the players provide an opportunity for the future growth of the market as well as enable the market players to gain maximum share in the market.

Research Methodology

The market study of the global diabetes care drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for diabetes care drug manufacturers, drug manufacturing companies, raw material suppliers, distributors, active pharmaceutical ingredient manufacturers, contract research organizations, contract manufacturers, investing companies, industry associations &experts, research institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Diabetes Care Drugs Market Research and Analysis by Drug Class

The Report covers:
  • Comprehensive research methodology of the global diabetes care drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global diabetes care drug market.
  • Insights about market determinants which are stimulating the global diabetes care drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Novo Nordisk A/S Overview Financial Analysis SWOT Analysis Recent Developments
3.1.2. Sanofi SA Overview Financial Analysis SWOT Analysis Recent Developments
3.1.3. AstraZeneca PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.1.4. Eli Lilly and Co. Overview Financial Analysis SWOT Analysis Recent Developments
3.1.5. Boehringer Ingelheim International GmbH Overview Financial Analysis SWOT Analysis Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Diabetes CareDrugs Market by Drug Class
5.1.1. Insulins
5.1.2. Non-Insulin Injectable Drugs
5.1.3. Oral Anti-Diabetic Drugs
5.1.4. Combination Drugs
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Astellas Pharma Inc.
7.2. AstraZeneca Plc
7.3. Bayer AG
7.4. Bausch Health Companies Inc.
7.5. Biocon Ltd.
7.6. Boehringer Ingelheim International GmbH
7.7. Bristol Myers Squibb Co.
7.8. Eli Lilly and Co.
7.9. Generex Biotechnology Corp.
7.10. Johnson & Johnson Services Inc.
7.11. Merck & Co. Inc.
7.12. Midatech Pharma Plc
7.13. Mylan NV
7.14. Novartis International AG
7.15. Novo Nordisk A/S
7.16. Oramed Pharmaceuticals Inc.
7.17. Pfizer Inc.
7.18. Sanofi SA
7.19. Takeda Pharmaceuticals Co.Ltd.
7.20. Teva Pharmaceuticals Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bausch Health Companies Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Eli Lilly and Company
  • Generex Biotechnology Corp.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Midatech Pharma Plc
  • Mylan NV
  • Novartis International AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceuticals Co. Ltd.
  • Teva Pharmaceuticals Industries Ltd.